Clinical efficacy was superior with bosutinib.
ONCOLOGY
Fully funded by 
Content independently selected
-
Chronic phase CML: bosutinib, imatinib yield similar effect on QoL -
AML: could pretransplant nutritional interventions improve OS? Findings from one of the largest studies of its kind.
-
CML: perceived relapse risk a key driver of TKI discontinuation Findings highlight need for improved decision support.
-
AACR 2019—Gilteritinib improves survival in FLT3-mutated AML Data from the phase 3 ADMIRAL trial led to U.S. regulatory approval.
-
B-cell precursor ALL: inotuzumab ozogamicin tops standard therapy Nearly 4 times as many patients went directly to HSCT.
-
CML: which tyrosine kinase inhibitor is safest? Study compares bosutinib, dasatinib, imatinib, nilotinib, ponatinib, and radotinib.
-
AML: pazopanib demonstrates limited efficacy in phase 2 study No significant reduction in BM microvessel density.
-
CLL: venetoclax-obinutuzumab induces deep, durable response Almost all patients responded, regardless of treatment line.
-
Elderly AML: intensive chemotherapy, decitabine offer similar OS Cytogenetic profile may help identify IC candidates.
-
CLL: broadening the scope of CAR T-cell therapy New studies involve combination regimens, multitargeted cells.
-
R/R Ph- B-cell ALL: study identifies the 3 components of "cure" Cure may be considered at 2-3 years off treatment.
-
NICE decision on blinatumomab for ALL in remission with MRD ≥0.1% Blinatumomab for acute lymphoblastic leukaemia in first or second complete remission with minimal residual disease of at least 0.1%
-
Pediatric CML: are adult data driving TKI discontinuation? STOP IMAPED shows low probability of sustained DMR.
-
R/R CLL: ibrutinib yields sustained PFS benefit in RESONATE Responses continued to deepen over time.